187 related articles for article (PubMed ID: 23549954)
1. Pamidronate treatment stimulates the onset of recovery phase reducing fracture rate and skeletal deformities in patients with idiopathic juvenile osteoporosis: comparison with untreated patients.
Baroncelli GI; Vierucci F; Bertelloni S; Erba P; Zampollo E; Giuca MR
J Bone Miner Metab; 2013 Sep; 31(5):533-43. PubMed ID: 23549954
[TBL] [Abstract][Full Text] [Related]
2. Assessment of bone quality by quantitative ultrasound of proximal phalanges of the hand and fracture rate in children and adolescents with bone and mineral disorders.
Baroncelli GI; Federico G; Bertelloni S; Sodini F; De Terlizzi F; Cadossi R; Saggese G
Pediatr Res; 2003 Jul; 54(1):125-36. PubMed ID: 12700367
[TBL] [Abstract][Full Text] [Related]
3. Effects of 3 years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG).
Bayram F; Tanriverdi F; Kurtoğlu S; Atabek ME; Kula M; Kaynar L; Keleştimur F
J Pediatr Endocrinol Metab; 2006 Mar; 19(3):275-9. PubMed ID: 16607930
[TBL] [Abstract][Full Text] [Related]
4. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
5. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.
Nasomyont N; Hornung LN; Gordon CM; Wasserman H
Bone; 2019 Apr; 121():60-67. PubMed ID: 30616029
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates for osteoporosis in people with cystic fibrosis.
Conwell LS; Chang AB
Cochrane Database Syst Rev; 2012 Apr; (4):CD002010. PubMed ID: 22513903
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD.
Baroncelli GI; Bertelloni S; Sodini F; Saggese G
Clin Endocrinol (Oxf); 2004 Feb; 60(2):175-84. PubMed ID: 14725678
[TBL] [Abstract][Full Text] [Related]
8. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study.
Krieg MA; Seydoux C; Sandini L; Goy JJ; Berguer DG; Thiébaud D; Burckhardt P
Osteoporos Int; 2001; 12(2):112-6. PubMed ID: 11303710
[TBL] [Abstract][Full Text] [Related]
9. Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation.
Barros ER; Dias da Silva MR; Kunii IS; Lazaretti-Castro M
J Pediatr Endocrinol Metab; 2008 Aug; 21(8):811-8. PubMed ID: 18825883
[TBL] [Abstract][Full Text] [Related]
10. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates for osteoporosis in people with cystic fibrosis.
Brenckmann C; Papaioannou A
Cochrane Database Syst Rev; 2001; (4):CD002010. PubMed ID: 11687132
[TBL] [Abstract][Full Text] [Related]
12. Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.
Andiran N; Alikasifoglu A; Gonc N; Ozon A; Kandemir N; Yordam N
J Pediatr Endocrinol Metab; 2008 Jan; 21(1):63-72. PubMed ID: 18404974
[TBL] [Abstract][Full Text] [Related]
13. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
Rauch F; Munns C; Land C; Glorieux FH
J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
[TBL] [Abstract][Full Text] [Related]
15. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.
Brown JJ; Zacharin MR
J Pediatr Endocrinol Metab; 2009 Jan; 22(1):55-63. PubMed ID: 19344075
[TBL] [Abstract][Full Text] [Related]
17. Effect of bisphosphonates on bone mineral density and fracture prevention in gastric cancer patients after gastrectomy.
Lim JS; Jin SH; Kim SB; Lee JI
J Clin Gastroenterol; 2012 Sep; 46(8):669-74. PubMed ID: 22504799
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of phalangeal quantitative ultrasound in identifying reduced bone mineral status and increased fracture risk in adolescents with Turner syndrome.
Vierucci F; Del Pistoia M; Erba P; Federico G; Saggese G
Hormones (Athens); 2014; 13(3):353-60. PubMed ID: 25079459
[TBL] [Abstract][Full Text] [Related]
19. Treatment with pamidronate for osteoporosis complicating long-term intestinal failure.
Pastore S; Londero M; Barbieri F; Di Leo G; Paparazzo R; Ventura A
J Pediatr Gastroenterol Nutr; 2012 Nov; 55(5):615-8. PubMed ID: 22614111
[TBL] [Abstract][Full Text] [Related]
20. Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis.
Gandrud LM; Cheung JC; Daniels MW; Bachrach LK
J Pediatr Endocrinol Metab; 2003; 16(6):887-92. PubMed ID: 12948302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]